Plain-English summary
Court affirms that Amgen's broad antibody patents are invalid for lack of enablement
The Court unanimously held that Amgen’s patent applications claiming all antibodies that bind and block PCSK9 were not enabled under the Patent Act because the patents failed to teach how to make and use the full scope of claimed antibodies. The Federal Circuit’s judgment invalidating the patents was affirmed.
Why this matters
The decision limits how broadly pharmaceutical and biotech companies can claim groups of molecules from a single patent. To secure broad 'genus' claims, patent filings must teach how to make and use substantially all members of the claimed class, not just a few examples. This affects incentives, competition, and how drug and biologic inventions are protected.
Who may feel it
- Biotech and pharmaceutical companies
- Patent filers and patent attorneys in life sciences
- Generic and biosimilar developers
- Investors in drug development
- Patients and health systems (indirectly, through competition and drug costs)
Key questions
- Does enablement under 35 U.S.C. §112(a) present a question of fact for a jury or a question of law reviewed by a court?
- What level of detail must a patent disclosure provide to enable a skilled person to make and use the full scope of a broad genus claim (such as all antibodies that bind and block a particular protein)?